Treatment of Thyroid Eye Disease

被引:0
|
作者
Margaret E. Phillips
Mehrak M. Marzban
Sajeev S. Kathuria
机构
[1] University of Maryland,Department of Ophthalmology
来源
关键词
West Nile Virus; Progressive Multifocal Leukoencephalopathy; Euthyroid State; Eyelid Retraction; Orbital Inflammation;
D O I
暂无
中图分类号
学科分类号
摘要
Thyroid eye disease (TED) is an autoimmune disease characterized by varying degrees of proptosis, congestion and inflammation of the extraocular tissues, and eyelid retraction. It is usually seen in the setting of Graves’ disease, but the severity of TED does not necessarily correlate with the level of systemic disease in a given patient. It is very important, nonetheless, to try to achieve a euthyroid state to minimize the chances of exacerbation of TED. Treatment of TED is based on the signs and symptoms displayed by the patient; there is no “one size fits all” approach. Generally, it is advisable to start with conservative measures, such as ocular lubrication with artificial tears, to manage symptoms of chronic irritation and redness. It is also imperative that the patient be advised to quit smoking, because there is a clear link between smoking and disease activity. Medical treatment with systemic oral or pulsed intravenous corticosteroids should be reserved for patients with active inflammation resulting in increased orbital pressure, compressive optic neuropathy, severe periorbital edema, or similar presentations. Once there is significant improvement in the acute inflammation, it is useful to treat patients who have residual inflammation with external beam radiation in order to be able to wean the patient off steroids and avoid their well-known complications.
引用
收藏
页码:64 / 69
页数:5
相关论文
共 50 条
  • [1] Treatment of Thyroid Eye Disease
    Phillips, Margaret E.
    Marzban, Mehrak M.
    Kathuria, Sajeev S.
    CURRENT TREATMENT OPTIONS IN NEUROLOGY, 2010, 12 (01) : 64 - 69
  • [2] Treatment Options for Thyroid Eye Disease
    Pillar, Angelique J.
    Richa, D. Chimene
    CURRENT TREATMENT OPTIONS IN NEUROLOGY, 2014, 16 (08)
  • [3] Teprotumumab for the treatment of thyroid eye disease
    Ju, Yongjing
    Yang, Junyi
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2020, 16 (08) : 739 - 743
  • [4] Treatment Options for Thyroid Eye Disease
    Angelique J. Pillar
    D. Chimene Richa
    Current Treatment Options in Neurology, 2014, 16
  • [5] Surgical treatment of thyroid eye disease
    Tallstedt, L
    THYROID, 1998, 8 (05) : 447 - 452
  • [6] Teprotumumab for the Treatment of Thyroid Eye Disease
    Ugradar, Shoaib
    Malkhasyan, Emil
    Douglas, Raymond S.
    ENDOCRINE REVIEWS, 2024, 45 (06) : 843 - 857
  • [7] Methotrexate for the Treatment of Thyroid Eye Disease
    Strianese, Diego
    Iuliano, Adriana
    Ferrara, Mariantonia
    Comune, Chiara
    Baronissi, Immacolata
    Napolitano, Pasquale
    D'Alessandro, Alessia
    Grassi, Piergiacomo
    Bonavolonta, Giulio
    Bonavolonta, Paola
    Sinisi, Antonio
    Tranfa, Fausto
    JOURNAL OF OPHTHALMOLOGY, 2014, 2014
  • [8] Ocular treatment of thyroid eye disease
    Eichhorn, Knut
    Harrison, Andrew R.
    Bothun, Erick D.
    McLoon, Linda K.
    Lee, Michael S.
    EXPERT REVIEW OF OPHTHALMOLOGY, 2010, 5 (03) : 313 - 324
  • [9] Thyroid Eye Disease: Pathogenesis and Treatment
    Sikder, Shameema
    Weinberg, Robert S.
    OPHTHALMOLOGICA, 2010, 224 (04) : 199 - 203
  • [10] Teprotumumab for the treatment of thyroid eye disease
    Fallahi, Poupak
    Ragusa, Francesca
    Paparo, Sabrina Rosaria
    Elia, Giusy
    Balestri, Eugenia
    Mazzi, Valeria
    Patrizio, Armando
    Botrini, Chiara
    Benvenga, Salvatore
    Ferrari, Silvia Martina
    Antonelli, Alessandro
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2023, 23 (02) : 123 - 131